Close Menu

NEW YORK (GenomeWeb) – Liquid biopsy test developer OncoCyte announced today its public offering of about 9.3 million shares of its common stock at $3.75 per share for gross proceeds of approximately $35 million.

The company has also granted the underwriters a 30-day option to purchase up to an additional 1.4 million shares of common stock at the public offering price to cover any overallotments.

Piper Jaffray is acting as the sole book-running manager and Janney Montgomery Scott is acting as the comanager for the offering, which should close on or about February 12.   

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Apr
23
Sponsored by
N-of-One

In 2016, the Association for Molecular Pathology (AMP), in partnership with the College of American Pathologists (CAP) and American College of Molecular Genetics (ACMG), launched a set of guidelines meant to set industry standards for reporting of molecular diagnostic test results in oncology, using a tier-based system and defined levels of evidence. 

Apr
24
Sponsored by
Biocrates

This webinar will provide a wide-ranging overview of the promise for metabolomics in studying human health and disease, as well as its potential for integration with other -omics disciplines.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.